GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (NAS:NVAX) » Definitions » Equity-to-Asset

Novavax (Novavax) Equity-to-Asset

: -0.40 (As of Dec. 2023)
View and export this data going back to 1995. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Novavax's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-716.9 Mil. Novavax's Total Assets for the quarter that ended in Dec. 2023 was $1,797.5 Mil. Therefore, Novavax's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -0.40.

The historical rank and industry rank for Novavax's Equity-to-Asset or its related term are showing as below:

NVAX' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.08   Med: -0.21   Max: 0.83
Current: -0.4

During the past 13 years, the highest Equity to Asset Ratio of Novavax was 0.83. The lowest was -1.08. And the median was -0.21.

NVAX's Equity-to-Asset is ranked worse than
88.31% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs NVAX: -0.40

Novavax Equity-to-Asset Historical Data

The historical data trend for Novavax's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.08 0.40 -0.14 -0.28 -0.40

Novavax Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.28 -0.58 -0.45 -0.41 -0.40

Competitive Comparison

For the Biotechnology subindustry, Novavax's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Novavax's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Novavax's Equity-to-Asset falls into.



Novavax Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Novavax's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-716.927/1797.49
=-0.40

Novavax's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-716.927/1797.49
=-0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novavax  (NAS:NVAX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Novavax Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Novavax's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Novavax (Novavax) Business Description

Traded in Other Exchanges
Address
21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.
Executives
Filip Dubovsky officer: President, R&D C/O NOVAVAX INC., 21 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Gregory M Glenn officer: President, R&D 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
Elaine O'hara officer: EVP, Chief Strategy Officer 333 NORTH WARREN AVENUE, MALVERN PA 19355
John C Jacobs director, officer: President and CEO 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Richard J Rodgers director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
James F Young director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Herrmann John A Iii officer: SVP, General Counsel C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Stanley C Erck director, officer: President and CEO 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
John Trizzino officer: SVP, CBO and CFO 9920 BELWARD CAMPUS DRIVE, ROCKVILLE MD 20850
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
James Patrick Kelly officer: EVP, CFO and Treasurer C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gary C Evans director 1048 TEXAN TRAIL, GRAPEVINE TX 76051
Rachel K. King director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Mcmanus Michael A Jr director 241-02 NORTHERN BLVD, DOUGLASTON NY 11362
Margaret G Mcglynn director C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100